StockNews.com Lowers iCAD (NASDAQ:ICAD) to Sell

iCAD (NASDAQ:ICAD) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.

iCAD Stock Up 2.9 %

iCAD stock traded up $0.04 during trading hours on Wednesday, hitting $1.40. The stock had a trading volume of 861,372 shares, compared to its average volume of 168,031. The stock’s 50-day moving average price is $1.34 and its 200-day moving average price is $1.49. The stock has a market capitalization of $37.16 million, a P/E ratio of -11.67 and a beta of 1.50. iCAD has a 12-month low of $1.18 and a 12-month high of $2.65.

iCAD (NASDAQ:ICAD) last announced its quarterly earnings data on Tuesday, May 14th. The technology company reported ($0.05) earnings per share for the quarter. The firm had revenue of $4.95 million during the quarter. iCAD had a negative return on equity of 14.00% and a negative net margin of 15.20%.

Hedge Funds Weigh In On iCAD

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC raised its holdings in shares of iCAD by 55.6% during the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after purchasing an additional 7,604 shares during the last quarter. Perritt Capital Management Inc. raised its stake in iCAD by 7.5% during the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after buying an additional 9,717 shares during the last quarter. First Eagle Investment Management LLC lifted its holdings in shares of iCAD by 2.8% during the 4th quarter. First Eagle Investment Management LLC now owns 679,525 shares of the technology company’s stock valued at $1,203,000 after buying an additional 18,689 shares during the period. Perritt Capital Management Inc boosted its stake in shares of iCAD by 14.2% in the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock worth $208,000 after buying an additional 19,917 shares during the last quarter. Finally, Salem Investment Counselors Inc. bought a new stake in shares of iCAD in the first quarter worth $119,000. Institutional investors own 24.61% of the company’s stock.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.